B
Bull
Bull · 25%ACON
$14.54
Scenario price
$2.400
-0.114 (-4.76%)At close
Loading chart…
- High
- 2.520
- Open
- 2.520
- VWAP
- 2.42
- Vol
- 35.25K
- Mkt Cap
- 2.45M
- Low
- 2.350
- Amount
- 85.43K
- EV/EBITDA, TTM
- 0.31
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
AI analysis of Aclarion Inc (ACON)
holdAclarion Inc is currently not a strong buy due to its low RSI of 39.87, indicating potential oversold conditions, and a significant year-to-date price drop of 51.81%. However, the company has shown a 196% year-over-year growth in Nociscan volumes, which may indicate future potential. The main risk is the negative net income, which was -2,747,551 USD in Q2 2026.
Valuation Metrics
The current forward P/E ratio for Aclarion Inc (ACON) is 0.00, compared to its 5-year average forward P/E of -1.20.
Alphio AI Price Scenarios for ACON
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
1.006-10NewsfilterAclarion to Present at Planet MicroCap Las Vegas 2026
- 8.506-08Newsfilter
Aclarion Rejects Echo Lake's Acquisition Proposal
- 8.506-08Newsfilter
Aclarion Stockholders Approve All Proposals at Annual Meeting
- 7.506-03Newsfilter
Aclarion Expands Nociscan Availability in Los Angeles Area
- 8.506-01Newsfilter
Aclarion Study Reveals Immune Links to Back Pain
ACON FAQ — answered by Alphio AI
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
Aclarion Inc is currently not a strong buy due to its low RSI of 39.87, indicating potential oversold conditions, and a significant year-to-date price drop of 51.81%. However, the company has shown a 196% year-over-year growth in Nociscan volumes, which may indicate future potential. The main risk is the negative net income, which was -2,747,551 USD in Q2 2026.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.